Literature DB >> 16730620

Anticholinergic medications in community-dwelling older veterans: prevalence of anticholinergic symptoms, symptom burden, and adverse drug events.

Jose Ness1, Angela Hoth, Mitchell J Barnett, Ronald I Shorr, Peter J Kaboli.   

Abstract

BACKGROUND: The use of drugs with anticholinergic adverse effects is often deemed inappropriate in elderly (aged > or = 65 years) patients, yet studies continue to show extensive use in this population at high risk for adverse drug events (ADEs). The burden of drug-related anticholinergic symptoms in community-dwelling elderly patients has not been well described.
OBJECTIVE: The aim of this study was to assess the prevalence of anticholinergic symptoms, corresponding symptom burden, and anticholinergic-related ADEs in a sample of community-dwelling elderly veterans.
METHODS: This prospective cohort study was conducted at the primary care clinics at the Veterans Affairs Medical Center (VAMC), Iowa City, Iowa. The study sample included randomly selected patients with intact cognitive function attending the VAMC and prescribed > or = 5 scheduled medications. Data on current prescription and nonprescription drug use were elicited by a trained research assistant and a clinical pharmacist from patient interviews and electronic medical records. The prevalence and severity of 7 anticholinergic symptoms (dry mouth, constipation, blurred vision, confusion, urinary hesitation, dry eyes, and drowsiness) were assessed at baseline. The occurrence of ADEs at 12 weeks was compared between patients using anticholinergic drugs and those not using them.
RESULTS: A total of 532 patients were included (97.9% men; mean age, 74.3 years; 27.1% used at least 1 anticholinergic drug). Twenty-two anticholinergic drugs (16 prescription medications, 6 over-the-counter medications) were identified. The mean number of anticholinergic symptoms was significantly higher in the group using anticholinergic drugs (3.1 vs 2.5; P < 0.01). However, only 2 symptoms were statistically more prevalent in the group using anticholinergic drugs: dry mouth (57.6% vs 45.6%) and constipation (42.4% vs 29.4%) (both, P < 0.01). At 12 weeks, only 1 (0.8%) patient in the group using anticholinergic drugs reported an ADE considered related to an anticholinergic drug.
CONCLUSIONS: Anticholinergic drug use was common (27.1%) in these elderly veterans with intact cognitive function. The mean number of anticholinergic symptoms was significantly greater in this group, and the prevalences of dry mouth and constipation were significantly higher in the group using anticholinergic drugs (all, P < 0.01). Anticholinergic-related ADEs were rare (0.8%). Although anticholinergic drugs should generally be avoided in the elderly, individual risks and benefits for a patient should be considered.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16730620     DOI: 10.1016/j.amjopharm.2006.03.008

Source DB:  PubMed          Journal:  Am J Geriatr Pharmacother        ISSN: 1876-7761


  42 in total

1.  Prevalence and predictors of anticholinergic medication use in elderly nursing home residents with dementia: analysis of data from the 2004 National Nursing Home Survey.

Authors:  Satabdi Chatterjee; Sandhya Mehta; Jeffrey T Sherer; Rajender R Aparasu
Journal:  Drugs Aging       Date:  2010-12-01       Impact factor: 3.923

2.  A preliminary study of anticholinergic burden and relationship to a quality of life indicator, engagement in activities, in nursing home residents with dementia.

Authors:  Ann Kolanowski; Donna M Fick; Judy Campbell; Mark Litaker; Malaz Boustani
Journal:  J Am Med Dir Assoc       Date:  2009-01-09       Impact factor: 4.669

3.  Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome.

Authors:  Erin M Hill-Burns; Justine W Debelius; James T Morton; William T Wissemann; Matthew R Lewis; Zachary D Wallen; Shyamal D Peddada; Stewart A Factor; Eric Molho; Cyrus P Zabetian; Rob Knight; Haydeh Payami
Journal:  Mov Disord       Date:  2017-02-14       Impact factor: 10.338

4.  Analysis of spatiotemporal pattern and quantification of gastrointestinal slow waves caused by anticholinergic drugs.

Authors:  Kelvin K L Wong; Lauren C Y Tang; Jerry Zhou; Vincent Ho
Journal:  Organogenesis       Date:  2017-02-23       Impact factor: 2.500

5.  Impact of multiple low-level anticholinergic medications on anticholinergic load of community-dwelling elderly with and without dementia.

Authors:  Karen E Mate; Karen P Kerr; Dimity Pond; Evan J Williams; John Marley; Peter Disler; Henry Brodaty; Parker J Magin
Journal:  Drugs Aging       Date:  2015-02       Impact factor: 3.923

6.  Systematic review of anticholinergic risk scales in older adults.

Authors:  Carlos E Durán; Majda Azermai; Robert H Vander Stichele
Journal:  Eur J Clin Pharmacol       Date:  2013-03-26       Impact factor: 2.953

7.  Central Anticholinergic Adverse Effects and Their Measurement.

Authors:  Pasi Lampela; Teemu Paajanen; Sirpa Hartikainen; Risto Huupponen
Journal:  Drugs Aging       Date:  2015-12       Impact factor: 3.923

8.  Association Between Anticholinergic Drug Use and Health-Related Quality of Life in Community-Dwelling Older Adults.

Authors:  Benoit Cossette; Maimouna Bagna; Modou Sene; Caroline Sirois; Gabrielle P Lefebvre; Olivier Germain; José A Morais; Pierrette Gaudreau; Hélène Payette
Journal:  Drugs Aging       Date:  2017-10       Impact factor: 3.923

9.  Drug interactions in dying patients: a retrospective analysis of hospice inpatients in Germany.

Authors:  Sebastian Frechen; Anna Zoeller; Klaus Ruberg; Raymond Voltz; Jan Gaertner
Journal:  Drug Saf       Date:  2012-09-01       Impact factor: 5.606

Review 10.  Over-Prescribed Medications, Under-Appreciated Risks: A Review of the Cognitive Effects of Anticholinergic Medications in Older Adults.

Authors:  Daniel M I Britt; Gregory S Day
Journal:  Mo Med       Date:  2016 May-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.